Caflanone

About Flavocure Biotech

Flavocure Biotech is a private, preclinical-stage biotech founded in 2018 and headquartered in Baltimore, MD. The company is developing a novel NanoCaflanone™ theranostic platform designed to deliver drugs across the blood-brain barrier, targeting neuroinflammation in diseases like Alzheimer's and Parkinson's, as well as tumor-associated macrophages in cancers like pancreatic cancer and glioblastoma. Its lead asset, Caflanone, is IND-ready for pancreatic cancer with FDA Orphan Drug designation, positioning the company to address areas with high mortality and limited treatment options.

Therapeutic Areas